COVID vaccine booster doses for omicron variants
On Aug 26, 2022, Pfizer and BioNTech announced that they had applied to the European Medicines Agency to have their omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine authorised as a booster dose. The companies submitted an equivalent application to the US Food and Drug Administration (FDA) on Aug 22. The vaccine combines mRNA coding for the spike protein of the Wuhan strain of SARS-CoV-2, which is the basis of the original Pfizer-BioNTech vaccine, with mRNA coding for the spike protein of the omicron BA.4 and BA.5 subvariants.